logo
Share SHARE
FONT-SIZE Plus   Neg

Aeterna: Final Phase 3 Results Show AEZS-130 Safe, Effective In Diagnosing AGHD

Aeterna Zentaris Inc. (AEZS, AEZ.TO) said that final Phase 3 results for its oral ghrelin agonist, AEZS-130, show that the drug is safe and effective in diagnosing adult growth hormone deficiency, or AGHD.

The multicenter open label study was originally designed as a cross-over trial of AEZS-130 vs growth hormone-releasing hormone (GHRH)+L-Arginine (ARG) in AGHD patients and in controls, matched for body mass index, estrogen status, gender and age. After 43 AGHD patients and 10 controls had been tested, GHRH became unavailable. The study was completed by testing 10 more AGHD patients and 38 controls with AEZS-130 alone.

The objective of the clinical trial was to determine the efficacy and safety of AEZS-130 in the diagnosis of AGHD.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Coca-Cola announced that it is removing its trademark logo from cans in the Middle East as part of the soda giant's marketing campaign to fight prejudice. The company has replaced its famous trademark logo with "Labels are for cans not people," message. The company has made the change during the... Carnival said it has obtained U.S. approval to begin cruises to Cuba. The announcement by the cruise operator follows the recent restoration of diplomatic relations between the U.S. and Cuba. GoPro has just launched a facile camera, its smallest and lightest yet, as the action-camera sports maker seeks to further entice its adventure-seeking consumers.
comments powered by Disqus
RELATED NEWS
Trade AEZS now with 
Follow RTT